Solstein Capital’s Biogen BIIB Stock Holding History

Solstein Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-115	Closed	-$33K	–	100
2020 Q3	$33K	Hold	115	–	–	0.07%	152
2020 Q2	$31K	Hold	115	–	–	0.07%	141
2020 Q1	$36K	Hold	115	–	–	0.14%	95
2019 Q4	$34K	Buy	+115	New	+$31.9K	0.07%	136

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Solstein Capital's BIIB Position: Q4 2020 in Review

Solstein Capital sold out of Biogen (BIIB) in Q4 2020, closing a stake of 115 shares — an estimated $33K sold.

Solstein Capital first reported a position in BIIB in Q4 2019 and held it in 4 quarters. The position peaked at $36K in Q1 2020. 1,062 funds tracked by Wall St. Rank hold BIIB as of Q4 2020.

Solstein Capital reported no remaining Biogen position as of Q4 2020 after selling out during the quarter.
Solstein Capital sold 115 Biogen shares in Q4 2020, an estimated $33K.
Solstein Capital first reported a position in Biogen in Q4 2019 and held it in 4 quarters.
Solstein Capital's Biogen position peaked at $36K in Q1 2020.
1,062 funds tracked by Wall St. Rank held Biogen as of Q4 2020.

Based on Solstein Capital's 13F filing for Q4 2020, filed 11 Feb 2021.